Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more Revealing the Chemistry Around Us Through Mass Spectrometry What Biotech Licensing Really Buys Beyond Conventional CRISPR Oral Sleep Apnea Therapy Poised to Expand Treatment Options Beyond the Payload Orphan Therapeutics Accelerator In-Licenses Its First Gene Therapy, Eyes Pipeline Expansion Tissue Engineering Takes Shape Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests STAT+: In China, a flood of controversial clinical trials slows to a trickle STAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debut STAT+: A possible comeback for a failed sickle cell gene therapy STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy Tetraploid Astrocytes Emerge as Potential Players in Drug-Resistant Temporal Lobe Epilepsy Ramaswamy’s biotech baggage haunted his political run From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026 The biggest biotech funding rounds in October 2026 Patient Advocacy Coffee Chat: Basic steps to being a good advocate BIO responds to Health Affairs Analysis, highlighting the importance of orphan drug incentives Pfizer eyes Europe first for Lyme vaccine as prevalence rises in US With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave Boehringer bets big on China, offering $7B biobucks for Sino cancer programs 1 in 5 have had multiple biopharma layoffs, poll finds Beyond the needle: The future of intratumoral therapy Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca T-time: British biotech pours $133M into the pot for bispecifics Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma Boehringer forges $7bn alliance with China’s SBP Group UK biotechs T-Therapeutics and Alethio score big financings Bayer’s Hyrnuo moves first-line for lung cancer in China Linking kinase inhibitors for greater selectivity Checkpoint inhibitor combinations: the trial-to-approval gap Degraders take on GPCRs STAT+: Pharma critic Bernie Sanders is set to hold major sway over FDA funding bill Novartis subsidiary Avidity will lay off 40 in San Diego Pritam International Private Limited – 738079 – 10/27/2026 Opioid Overdose Reversal Medications Medications for Opioid Use Disorder (MOUD) Generic Competition and Drug Prices PDUFA and BsUFA Quarterly Hiring Updates FDA Pediatric Safety Communications STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug Biopharma likely to climb higher after ‘blue wave,’ analysts say Radiopharma venture money moves toward alpha emitters FDA needs a roadmap for disease-agnostic drug development — a Perspective Caspian: Regenerating beta cells with a menin inhibitor With Vidya acquisition, Gujrathi takes chair role at Processa Home